Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort

Tomas Olsson; Anat Achiron; Lars Alfredsson; Thomas Berger; David Brassat; Andrew Chan; Giancarlo Comi; Mefkure Eraksoy; Harald Hegen; Jan Hillert; Poul Erik Hyldgaard Jensen; Lucia Moiola; Kjell Morten Myhr; Annette Oturai; Sven Schippling; Aksel Siva; Per Soelberg Sorensen; Anne Kathrin Trampe; Thomas Weber; James Potts; Tatiana Plavina; Dominic Paes; Meena Subramanyam; Heinz Wiendl; Hussein Dib; Deniz Üren; Bernhard Hemmer; Dorothea Buck

doi:10.1177/1352458513477925

Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort

Tomas Olsson, Anat Achiron, Lars Alfredsson, Thomas Berger, David Brassat, Andrew Chan, Giancarlo Comi, Mefkure Eraksoy, Harald Hegen, Jan Hillert, Poul Erik Hyldgaard Jensen, Lucia Moiola, Kjell Morten Myhr, Annette Oturai, Sven Schippling, Aksel Siva, Per Soelberg Sorensen, Anne Kathrin Trampe, Thomas Weber, James PottsTatiana Plavina, Dominic Paes, Meena Subramanyam, Heinz Wiendl, Hussein Dib, Deniz Üren, Bernhard Hemmer, Dorothea Buck

IRCCS Ospedale San Raffaele

Research output: Contribution to journal › Article › peer-review

Abstract

JC virus (JCV) is an opportunistic virus known to cause progressive multifocal leukoencephalopathy. Anti-JC virus (Anti-JCV) antibody prevalence in a large, geographically diverse, multi-national multiple sclerosis (MS) cohort was compared in a cross-sectional study. Overall, anti-JCV antibody prevalence was 57.6%. Anti-JCV antibody prevalence in MS patients ranged from approximately 47% to 68% across these countries: Norway, 47.4%; Denmark, 52.6%; Israel, 56.6%; France, 57.6%; Italy, 58.3%; Sweden, 59.0%; Germany, 59.1%; Austria, 66.7% and Turkey, 67.7%. Prevalence increased with age (from 49.5% in patients <30 years of age to 66.5% in patients ≥ 60 years of age; p <0.0001 comparing all age categories), was lower in females than in males (55.8% versus 61.9%; p <0.0001) and was not affected by prior immunosuppressant or natalizumab use.

Original language	English
Pages (from-to)	1533-1538
Number of pages	6
Journal	Multiple Sclerosis Journal
Volume	19
Issue number	11
DOIs	https://doi.org/10.1177/1352458513477925
Publication status	Published - 2013

Keywords

anti-JCV antibodies
antibody prevalence
brain infection
epidemiology
immunosuppressant therapy
infection risk
international study
JC virus
Multiple sclerosis
natalizumab
STRATIFY-JCV

ASJC Scopus subject areas

Clinical Neurology
Neurology

Access to Document

10.1177/1352458513477925

Fingerprint Dive into the research topics of 'Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort'. Together they form a unique fingerprint.

Cite this

Olsson, T., Achiron, A., Alfredsson, L., Berger, T., Brassat, D., Chan, A., Comi, G., Eraksoy, M., Hegen, H., Hillert, J., Jensen, P. E. H., Moiola, L., Myhr, K. M., Oturai, A., Schippling, S., Siva, A., Sorensen, P. S., Trampe, A. K., Weber, T., ... Buck, D. (2013). Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort. Multiple Sclerosis Journal, 19(11), 1533-1538. https://doi.org/10.1177/1352458513477925

Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort. / Olsson, Tomas; Achiron, Anat; Alfredsson, Lars; Berger, Thomas; Brassat, David; Chan, Andrew; Comi, Giancarlo; Eraksoy, Mefkure; Hegen, Harald; Hillert, Jan; Jensen, Poul Erik Hyldgaard; Moiola, Lucia; Myhr, Kjell Morten; Oturai, Annette; Schippling, Sven; Siva, Aksel; Sorensen, Per Soelberg; Trampe, Anne Kathrin; Weber, Thomas; Potts, James; Plavina, Tatiana; Paes, Dominic; Subramanyam, Meena; Wiendl, Heinz; Dib, Hussein; Üren, Deniz; Hemmer, Bernhard; Buck, Dorothea.

In: Multiple Sclerosis Journal, Vol. 19, No. 11, 2013, p. 1533-1538.

Research output: Contribution to journal › Article › peer-review

Olsson, T, Achiron, A, Alfredsson, L, Berger, T, Brassat, D, Chan, A, Comi, G, Eraksoy, M, Hegen, H, Hillert, J, Jensen, PEH, Moiola, L, Myhr, KM, Oturai, A, Schippling, S, Siva, A, Sorensen, PS, Trampe, AK, Weber, T, Potts, J, Plavina, T, Paes, D, Subramanyam, M, Wiendl, H, Dib, H, Üren, D, Hemmer, B & Buck, D 2013, 'Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort', Multiple Sclerosis Journal, vol. 19, no. 11, pp. 1533-1538. https://doi.org/10.1177/1352458513477925

Olsson, Tomas ; Achiron, Anat ; Alfredsson, Lars ; Berger, Thomas ; Brassat, David ; Chan, Andrew ; Comi, Giancarlo ; Eraksoy, Mefkure ; Hegen, Harald ; Hillert, Jan ; Jensen, Poul Erik Hyldgaard ; Moiola, Lucia ; Myhr, Kjell Morten ; Oturai, Annette ; Schippling, Sven ; Siva, Aksel ; Sorensen, Per Soelberg ; Trampe, Anne Kathrin ; Weber, Thomas ; Potts, James ; Plavina, Tatiana ; Paes, Dominic ; Subramanyam, Meena ; Wiendl, Heinz ; Dib, Hussein ; Üren, Deniz ; Hemmer, Bernhard ; Buck, Dorothea. / Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort. In: Multiple Sclerosis Journal. 2013 ; Vol. 19, No. 11. pp. 1533-1538.

@article{48f66ba13a6241aa9ea4da74f99777b3,

title = "Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort",

abstract = "JC virus (JCV) is an opportunistic virus known to cause progressive multifocal leukoencephalopathy. Anti-JC virus (Anti-JCV) antibody prevalence in a large, geographically diverse, multi-national multiple sclerosis (MS) cohort was compared in a cross-sectional study. Overall, anti-JCV antibody prevalence was 57.6%. Anti-JCV antibody prevalence in MS patients ranged from approximately 47% to 68% across these countries: Norway, 47.4%; Denmark, 52.6%; Israel, 56.6%; France, 57.6%; Italy, 58.3%; Sweden, 59.0%; Germany, 59.1%; Austria, 66.7% and Turkey, 67.7%. Prevalence increased with age (from 49.5% in patients <30 years of age to 66.5% in patients ≥ 60 years of age; p <0.0001 comparing all age categories), was lower in females than in males (55.8% versus 61.9%; p <0.0001) and was not affected by prior immunosuppressant or natalizumab use.",

keywords = "anti-JCV antibodies, antibody prevalence, brain infection, epidemiology, immunosuppressant therapy, infection risk, international study, JC virus, Multiple sclerosis, natalizumab, STRATIFY-JCV",

author = "Tomas Olsson and Anat Achiron and Lars Alfredsson and Thomas Berger and David Brassat and Andrew Chan and Giancarlo Comi and Mefkure Eraksoy and Harald Hegen and Jan Hillert and Jensen, {Poul Erik Hyldgaard} and Lucia Moiola and Myhr, {Kjell Morten} and Annette Oturai and Sven Schippling and Aksel Siva and Sorensen, {Per Soelberg} and Trampe, {Anne Kathrin} and Thomas Weber and James Potts and Tatiana Plavina and Dominic Paes and Meena Subramanyam and Heinz Wiendl and Hussein Dib and Deniz {\"U}ren and Bernhard Hemmer and Dorothea Buck",

year = "2013",

doi = "10.1177/1352458513477925",

language = "English",

volume = "19",

pages = "1533--1538",

journal = "Multiple Sclerosis",

issn = "1352-4585",

publisher = "SAGE Publications Ltd",

number = "11",

}

TY - JOUR

T1 - Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort

AU - Olsson, Tomas

AU - Achiron, Anat

AU - Alfredsson, Lars

AU - Berger, Thomas

AU - Brassat, David

AU - Chan, Andrew

AU - Comi, Giancarlo

AU - Eraksoy, Mefkure

AU - Hegen, Harald

AU - Hillert, Jan

AU - Jensen, Poul Erik Hyldgaard

AU - Moiola, Lucia

AU - Myhr, Kjell Morten

AU - Oturai, Annette

AU - Schippling, Sven

AU - Siva, Aksel

AU - Sorensen, Per Soelberg

AU - Trampe, Anne Kathrin

AU - Weber, Thomas

AU - Potts, James

AU - Plavina, Tatiana

AU - Paes, Dominic

AU - Subramanyam, Meena

AU - Wiendl, Heinz

AU - Dib, Hussein

AU - Üren, Deniz

AU - Hemmer, Bernhard

AU - Buck, Dorothea

PY - 2013

Y1 - 2013

N2 - JC virus (JCV) is an opportunistic virus known to cause progressive multifocal leukoencephalopathy. Anti-JC virus (Anti-JCV) antibody prevalence in a large, geographically diverse, multi-national multiple sclerosis (MS) cohort was compared in a cross-sectional study. Overall, anti-JCV antibody prevalence was 57.6%. Anti-JCV antibody prevalence in MS patients ranged from approximately 47% to 68% across these countries: Norway, 47.4%; Denmark, 52.6%; Israel, 56.6%; France, 57.6%; Italy, 58.3%; Sweden, 59.0%; Germany, 59.1%; Austria, 66.7% and Turkey, 67.7%. Prevalence increased with age (from 49.5% in patients <30 years of age to 66.5% in patients ≥ 60 years of age; p <0.0001 comparing all age categories), was lower in females than in males (55.8% versus 61.9%; p <0.0001) and was not affected by prior immunosuppressant or natalizumab use.

AB - JC virus (JCV) is an opportunistic virus known to cause progressive multifocal leukoencephalopathy. Anti-JC virus (Anti-JCV) antibody prevalence in a large, geographically diverse, multi-national multiple sclerosis (MS) cohort was compared in a cross-sectional study. Overall, anti-JCV antibody prevalence was 57.6%. Anti-JCV antibody prevalence in MS patients ranged from approximately 47% to 68% across these countries: Norway, 47.4%; Denmark, 52.6%; Israel, 56.6%; France, 57.6%; Italy, 58.3%; Sweden, 59.0%; Germany, 59.1%; Austria, 66.7% and Turkey, 67.7%. Prevalence increased with age (from 49.5% in patients <30 years of age to 66.5% in patients ≥ 60 years of age; p <0.0001 comparing all age categories), was lower in females than in males (55.8% versus 61.9%; p <0.0001) and was not affected by prior immunosuppressant or natalizumab use.

KW - anti-JCV antibodies

KW - antibody prevalence

KW - brain infection

KW - epidemiology

KW - immunosuppressant therapy

KW - infection risk

KW - international study

KW - JC virus

KW - Multiple sclerosis

KW - natalizumab

KW - STRATIFY-JCV

UR - http://www.scopus.com/inward/record.url?scp=84884552568&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884552568&partnerID=8YFLogxK

U2 - 10.1177/1352458513477925

DO - 10.1177/1352458513477925

M3 - Article

C2 - 23459571

AN - SCOPUS:84884552568

VL - 19

SP - 1533

EP - 1538

JO - Multiple Sclerosis

JF - Multiple Sclerosis

SN - 1352-4585

IS - 11

ER -